PMID- 37310644 OWN - NLM STAT- MEDLINE DCOM- 20231012 LR - 20240124 IS - 1573-2576 (Electronic) IS - 0360-3997 (Linking) VI - 46 IP - 5 DP - 2023 Oct TI - Acetyl-11-Keto-Beta-Boswellic Acid Has Therapeutic Benefits for NAFLD Rat Models That Were Given a High Fructose Diet by Ameliorating Hepatic Inflammation and Lipid Metabolism. PG - 1966-1980 LID - 10.1007/s10753-023-01853-y [doi] AB - Acetyl-11-keto-beta-boswellic acid (AKBA), a potent anti-inflammatory compound purified from Boswellia species, was investigated in a preclinical study for its potential in preventing and treating non-alcoholic fatty liver disease (NAFLD), the most common chronic inflammatory liver disorder. The study involved thirty-six male Wistar rats, equally divided into prevention and treatment groups. In the prevention group, rats were given a high fructose diet (HFrD) and treated with AKBA for 6 weeks, while in the treatment group, rats were fed HFrD for 6 weeks and then given a normal diet with AKBA for 2 weeks. At the end of the study, various parameters were analyzed including liver tissues and serum levels of insulin, leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-beta), interferon gamma (INF-Upsilon), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha). Additionally, the expression levels of genes related to the inflammasome complex and peroxisome proliferator-activated receptor gamma (PPAR-Upsilon), as well as the levels of phosphorylated and non-phosphorylated AMP-activated protein kinase alpha-1 (AMPK-alpha1) protein, were measured. The results showed that AKBA improved NAFLD-related serum parameters and inflammatory markers and suppressed PPAR-Upsilon and inflammasome complex-related genes involved in hepatic steatosis in both groups. Additionally, AKBA prevented the reduction of the active and inactive forms of AMPK-alpha1 in the prevention group, which is a cellular energy regulator that helps suppress NAFLD progression. In conclusion, AKBA has a beneficial effect on preventing and avoiding the progression of NAFLD by preserving lipid metabolism, improving hepatic steatosis, and suppressing liver inflammation. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kachouei, Reza Ataei AU - Kachouei RA AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Doagoo, Alireza AU - Doagoo A AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Jalilzadeh, Maral AU - Jalilzadeh M AD - Science and Research Branch, Islamic Azad University, Tehran, Iran. FAU - Khatami, Seyyed Hossein AU - Khatami SH AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Rajaei, Shima AU - Rajaei S AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Jahan-Abad, Ali Jahanbazi AU - Jahan-Abad AJ AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. AD - Department of Anatomy, Physiology and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada. FAU - Salmani, Farzaneh AU - Salmani F AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Pakrad, Roya AU - Pakrad R AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Baram, Somayeh Mahmoodi AU - Baram SM AD - Clinical Trial Department, Behbalin Inc, Tehran, Iran. FAU - Nourbakhsh, Mitra AU - Nourbakhsh M AD - Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. FAU - Abdollahifar, Mohammad-Amin AU - Abdollahifar MA AD - Department of Biology and Anatomy, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Abbaszadeh, Hojjat Allah AU - Abbaszadeh HA AD - Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Noori, Shokoofeh AU - Noori S AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Rezaei, Mitra AU - Rezaei M AD - Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Mahdavi, Meisam AU - Mahdavi M AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Shahmohammadi, Mohammad Reza AU - Shahmohammadi MR AD - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. FAU - Karima, Saeed AU - Karima S AD - Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. saeed.karima@sbmu.ac.ir. LA - eng PT - Journal Article DEP - 20230613 PL - United States TA - Inflammation JT - Inflammation JID - 7600105 RN - 0 (acetyl-11-ketoboswellic acid) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - 0 (Inflammasomes) RN - 30237-26-4 (Fructose) RN - 0 (Peroxisome Proliferator-Activated Receptors) SB - IM MH - Rats MH - Male MH - Animals MH - *Non-alcoholic Fatty Liver Disease/drug therapy/metabolism MH - AMP-Activated Protein Kinases/metabolism MH - Inflammasomes/metabolism MH - Fructose/metabolism/pharmacology/therapeutic use MH - Lipid Metabolism MH - Peroxisome Proliferator-Activated Receptors/metabolism MH - Rats, Wistar MH - Liver/metabolism MH - Diet MH - Inflammation/metabolism OTO - NOTNLM OT - AMP-activated protein kinase (AMPK) OT - Acetyl-11-keto-beta-boswellic acid (AKBA) OT - Inflammasome OT - Non-alcoholic fatty liver disease (NAFLD) OT - Peroxisome proliferator-activated receptor gamma (PPAR-Upsilon) EDAT- 2023/06/13 13:12 MHDA- 2023/10/12 06:43 CRDT- 2023/06/13 11:13 PHST- 2023/01/26 00:00 [received] PHST- 2023/06/05 00:00 [accepted] PHST- 2023/05/31 00:00 [revised] PHST- 2023/10/12 06:43 [medline] PHST- 2023/06/13 13:12 [pubmed] PHST- 2023/06/13 11:13 [entrez] AID - 10.1007/s10753-023-01853-y [pii] AID - 10.1007/s10753-023-01853-y [doi] PST - ppublish SO - Inflammation. 2023 Oct;46(5):1966-1980. doi: 10.1007/s10753-023-01853-y. Epub 2023 Jun 13.